Artivion (AORT) has drawn fresh attention after recent share price swings, with the stock up 3.1% in the latest session but still down 38.8% year to date as of 27 August 2026.
Artivion's recent 1 day share price return of 3.11% comes after a 7 day share price decline of 5.62%, with the stock still showing a year to date share price loss of 38.82%. The 3 year total shareholder return is 55.25%, suggesting longer term holders have seen a very different experience to recent buyers.
Balance Artivion's recent volatility by scanning a hand picked list of solid balance sheet and fundamentals (51 results) that may offer a steadier profile alongside this healthcare stock's sharp year to date declines.
For a stock like Artivion, a sharp year to date fall followed by a short term bounce can reflect either changing views on the business or just sentiment whiplash. So what story does the current valuation tell?
Most Popular Narrative: 35.2% Undervalued
Analysts following Artivion see a fair value of $42 per share compared with the latest close at $27.20, and they anchor that view in a specific growth and product rollout story.
Ongoing U.S. launch of AMDS, with positive physician feedback, rapid clinical adoption post-training, and a significant $150 million annual market opportunity, indicates accelerating market penetration, this should materially contribute to both top-line revenue growth and high-margin product mix, improving EBITDA margins long-term.
Curious what sits behind that $42 fair value label on Artivion. The narrative leans on multi year revenue expansion, rising margins, and a richer product mix. Want to see how those moving parts are stitched together into one valuation story.
Result: Fair Value of $42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Artivion story can change quickly if regulatory approvals are delayed or if hospitals push back on pricing, which could pressure revenue and margins.
Find out about the key risks to this Artivion narrative.
Another View on Artivion: DCF Points to a Tighter Picture
The analyst narrative suggests Artivion is undervalued by 35.2% based on a $42 fair value. Our DCF model tells a much closer story, with an estimated future cash flow value of $26.95 against the current $27.20 share price, which implies the stock is slightly overvalued on this measure. Which lens do you treat as more important for your own work?
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Artivion for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With such a mixed picture around Artivion right now, this is a moment to move quickly and weigh the data yourself. Balance the concerns and potential upsides by digging into the 3 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Artivion?
If you only stop with Artivion, you may miss other opportunities that fit your goals. Use the Simply Wall St screener to widen your watchlist intelligently.
-
Target potential mispricings by reviewing companies that screen as quality yet overlooked through the 51 high quality undervalued stocks .
-
Prioritize resilience by focusing on businesses that show stronger financial footing using the 75 resilient stocks with low risk scores .
-
Hunt for future leaders early by scanning financially sound smaller companies within the 23 elite penny stocks with strong financials .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AORT .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
